Abstract Fat mass, long viewed as a passive reservoir for excess energy, has undergone a paradigm shift in biomedical research. Over the past decade, technological breakthroughs in single-cell genomics, advanced imaging, and targeted metabolomics have redefined adipose tissue as a highly dynamic, plastic, and immunologically active organ. This review highlights recent advances in our understanding of fat mass heterogeneity, the discovery of novel adipokine signaling pathways, the role of adipose tissue in systemic inflammation and cachexia, and emerging therapeutic strategies that leverage fat mass biology—from cold-induced beige adipogenesis to CRISPR-based modulation of lipid storage. We also discuss unresolved challenges, including the tissue-specific measurement of fat mass in vivo and the need for sex- and depot-aware research frameworks.

1. Introduction: Beyond the Adipocyte Adipose tissue comprises not only mature adipocytes but also a complex stroma of preadipocytes, endothelial cells, fibroblasts, and a rich repertoire of immune cells—most notably adipose tissue macrophages (ATMs) and regulatory T cells (Tregs). The functional state of fat mass is now recognized as a critical determinant of metabolic health, independent of body mass index (BMI). Recent work by Rosen and Spiegelman (2020) has emphasized that fat mass expansion in subcutaneous depots is generally protective, whereas visceral and ectopic fat accumulation correlates with insulin resistance and cardiovascular risk. This depot-specificity has driven a new wave of research into the molecular signatures that govern fat distribution.

2. Single-Cell and Spatial Transcriptomics: Mapping Fat Mass Heterogeneity A landmark technical advance is the application of single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics to adipose tissue. In 2023, Bäckdahl et al. published a comprehensive human adipose tissue atlas, identifying distinct adipocyte subtypes with differential expression of genes involved in lipolysis, thermogenesis, and extracellular matrix remodeling. Notably, they discovered a novel population of "stress-responsive" adipocytes that express high levels of SERPINE1 and IL-6, linking local fat mass dysfunction to systemic inflammation. Concurrently, spatial transcriptomic studies by Emont et al. (2022) revealed that immune cells are not uniformly distributed within fat pads; instead, they form discrete micro-niches around dying adipocytes, termed "crown-like structures." These structures are now considered the epicenter of adipose tissue inflammation and a potential therapeutic target.

3. Adipokine Discovery and the Endocrine Function of Fat Mass The identification of novel adipokines has expanded our understanding of fat mass as an endocrine organ. Beyond leptin and adiponectin, recent studies have highlighted the role of:

4. Technological Breakthroughs in Fat Mass Quantification Accurate measurement of fat mass remains a cornerstone for both research and clinical practice. While dual-energy X-ray absorptiometry (DXA) and MRI are standard, recent innovations include:

5. Immunometabolism and Fat Mass: The Macrophage–Adipocyte Circuit A major conceptual advance is the recognition of a bidirectional communication loop between adipocytes and immune cells. In obesity, adipocyte hypertrophy triggers mechanical stress and hypoxia, leading to the release of damage-associated molecular patterns (DAMPs) such as HMGB1 and free fatty acids. These activate ATMs via TLR4 and NLRP3 inflammasome pathways, shifting them from an M2-like (anti-inflammatory) to an M1-like (pro-inflammatory) phenotype. In turn, M1 macrophages secrete TNF-α and IL-1β, which impair adipocyte insulin signaling and promote lipolysis. A breakthrough study by Li et al. (2024) showed that targeting the macrophage-specific receptor TREM2 with a small-molecule agonist reverses this circuit, restoring insulin sensitivity and reducing fat mass in diet-induced obese mice by 23% without affecting food intake.

6. Beige Fat and the Quest for "Healthy" Fat Mass Expansion The discovery of recruitable beige adipocytes within white fat depots has opened new avenues for therapeutic fat mass modulation. Cold exposure and β3-adrenergic receptor agonists (e.g., mirabegron) have been shown to induce beige adipogenesis, increasing mitochondrial uncoupling protein 1 (UCP1) expression. However, clinical translation has been hampered by poor bioavailability and cardiovascular side effects. Recent progress includes:

7. Fat Mass in Cachexia and Cancer: A Double-Edged Sword While obesity-associated fat mass expansion is harmful, excessive fat loss—cachexia—is equally detrimental. In cancer patients, tumor-derived factors such as parathyroid hormone-related protein (PTHrP) and IL-6 drive adipocyte lipolysis and white-to-beige transition, leading to rapid fat mass depletion. A 2023 multi-center study by Wu et al. found that preserving fat mass via β-hydroxy-β-methylbutyrate (HMB) supplementation improved survival in pancreatic cancer patients by 2.1 months, independent of muscle mass. This highlights the necessity of maintaining an optimal fat mass range, rather than simply reducing it.

8. Future Directions and Unresolved Questions Despite these advances, several challenges remain. First, the field lacks a unified, non-invasive method to measure fat mass in real-time across different depots with high resolution; current imaging modalities are either expensive or lack lipid specificity. Second, most mechanistic studies rely on rodent models, which have distinct fat distribution and immune profiles compared to humans. Third, sex differences in fat mass regulation are profound—estrogen promotes subcutaneous fat accumulation while testosterone favors visceral fat—yet many trials still underreport sex-stratified data. Future research should focus on:

9. Conclusion Fat mass is no longer a passive bystander in metabolic disease. The integration of high-resolution molecular profiling, advanced imaging, and immunometabolic insights has transformed our understanding of this tissue. The next decade will likely witness the translation of these discoveries into precision therapies that modulate fat mass quality and distribution—rather than simply reducing total quantity—to achieve metabolic resilience.

References